 CAMBRIDGE, Mass., VANCOUVER, Wash.--BUSINESS WIRE--EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and Absci Corporation Nasdaq: ABSI, the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced a discovery collaboration. The partnership will leverage Abscis Drug CreationTM technology for discovery and 